Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin

Guan, Tiffany; Lo, Mimi; Young, Rebecca; Ai, Weiyun Z.; Boulbol, Fouad; Mouanoutoua, Hanson; Chu, Raymond; Andreadis, Charalambos; Kaplan, Lawrence; Abdulhaq, Haifaa; Fakhri, Bita

doi:10.1080/10428194.2022.2100369

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 This complication is not well-described, though phase 1 studies of BV noted a high rate of lung injury when BV was added to ABVD (44%). In 1 retrospective study of 123 adult and pediatric patients receiving BV for cHL, 5% developed pneumonitis, 27 and several other case reports have detailed the finding. 28 , 29 , 30 , 31 Our findings emphasize the need to consider BV-associated pneumonitis in patients who develop pulmonary symptoms during treatment.…”

Section: Discussionmentioning

confidence: 96%

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort

Bowers,

Anna,

Bair

et al. 2023

Blood Advances

View full text Add to dashboard Cite

Introduction: Brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is increasingly used for frontline treatment of stage III/IV classical Hodgkin lymphoma (cHL). Peripheral neuropathy (PN) was the most common and treatment-limiting side effect seen in clinical trials but has not been studied in a non-trial setting, where clinicians may have different strategies for managing it. Methods: We conducted a multi-site retrospective study to characterize PN in patients who received BV+AVD for newly diagnosed cHL. Results: 153 patients from 10 US institutions were eligible. Thirty-four patients (22%) had at least 1 ineligibility criteria for ECHELON-1, including stage, performance status, and comorbidities. PN was reported by 80% of patients during treatment; 39% experienced grade (G) 1, 31% G2, and 10% G3. In total, BV was modified in 44% of patients due to PN leading to BV discontinuation in 23%, dose reduction in 17%, and temporary hold in 4%. With a median follow up of 24 months, PN resolution was documented in 36% and improvement in 33% at last follow up. 2-year progression-free survival (PFS) for the advanced stage patients was 82.7% (95% CI 0.76-0.90) and overall survival (OS) was 97.4% (95% CI 0.944-1.00). Patients who discontinued BV due to PN did not have inferior PFS. Conclusions: In the non-trial setting, BV+AVD was associated with a high incidence of PN. In our cohort, which includes patients who would not have been eligible for the pivotal ECHELON-1 trial, BV discontinuation rates were higher than previously reported, but 2-year outcomes remain comparable.

show abstract